Merck stock steadies as Keytruda drives growth and investors weigh pipeline momentum

Merck & Co. stock, listed on the NYSE under the ticker MRK and part of the S&P 500 index, has recently traded close to its 52-week high, underlining how the US pharmaceutical group’s oncology franchise and broad pipeline continue to shape investor sentiment. As of 30 April 2024, according to Merck’s first quarter 2024 earnings release, the company reported solid revenue growth and highlighted Keytruda as a central earnings driver, reinforcing the fundamental backdrop behind the share price.

Revenue up 9 percent in Q1 2024

In its first quarter 2024 report, Merck & Co. stated that worldwide sales reached approximately $15.8 billion, representing about 9% growth compared with the same period in 2023 when revenue was roughly $14.5 billion, as detailed by the Q1 2024 financial results. This increase was driven primarily by oncology and cardiovascular products, with Keytruda again the largest single contributor to sales and a key reason why Merck stock remains supported by fundamental growth rather than purely defensive positioning.

Merck reported that Keytruda delivered around $6.9 billion of revenue in Q1 2024, up from approximately $5.8 billion in the prior-year quarter, implying year-on-year growth of roughly 19%, according to the same earnings release. For investors, that double-digit expansion in a flagship oncology product underlines Merck’s ability to extend Keytruda’s lifecycle through new indications and combinations, helping to offset the longer-term challenge of eventual patent expiry.

Operating performance, EPS and dividend metrics

Beyond top-line expansion, Merck & Co. also reported that GAAP earnings per share (EPS) from continuing operations reached about $1.28 in Q1 2024, compared with roughly $1.11 a year earlier, as indicated in the first quarter financial report. On an adjusted basis, EPS came in near $2.07, modestly above the prior-year figure of about $1.96, reflecting higher sales and an evolving mix of R&D and marketing expenses. The progression in EPS helps explain why Merck stock has been able to hold gains even as global interest rate expectations and sector rotation periodically weigh on large-cap healthcare names.

Merck’s operating performance in Q1 2024 included a reported GAAP net income of roughly $3.3 billion, up from about $2.8 billion a year earlier, underscoring the leverage from Keytruda and other growth drivers across oncology and vaccines, according to Merck’s Q1 2024 release. For shareholders, the combination of expanding net income and a robust cash flow base provides support for Merck’s dividend policy and continued investment in pipeline assets, a balance that often matters as much as headline revenue growth in the pharma sector.

Merck & Co. has also emphasized its shareholder returns through a regular dividend. As disclosed in the same reporting period, the company paid a quarterly dividend of $0.73 per share, implying an annualized payout of $2.92 per share if maintained throughout 2024, as noted by Merck’s dividend information. In the context of Merck stock’s valuation and yield, that dividend level is a core component of the investment case for income-oriented investors, particularly when compared against prevailing US Treasury yields and sector peers.

R&D investment and pipeline commitments

In the first quarter of 2024, Merck & Co. reported research and development expenses of around $3.3 billion, slightly above roughly $3.0 billion in the prior-year quarter, based on data from its Q1 2024 results. That increase of about 10% illustrates Merck’s strategy of reinvesting a meaningful portion of cash flow into new oncology, infectious disease and cardiovascular assets, a factor that may weigh on margins in the near term but is intended to sustain revenue beyond the current Keytruda cycle.

For long-term holders of Merck stock, the scale of R&D spending provides a useful signal about management’s confidence in the pipeline and willingness to pursue acquisitions or licensing deals when they complement internal programs. Higher R&D can compress operating margins relative to some peers in the short run, yet in pharmaceuticals it is often seen as a prerequisite for future launches that can replace revenue from products approaching patent cliffs. Merck’s decision to hold R&D at a high level in Q1 2024 reflects that trade-off in a tangible way.

Merck’s capital allocation also includes selective business development. In recent years the company has announced and completed various collaborations and acquisitions in immunology and oncology designed to deepen its pipeline, and Q1 2024 commentary continued to highlight business development as a priority, according to statements summarized in Merck’s earnings materials. For investors, these strategic moves help frame Merck stock not only as a defensive dividend payer but as a company still pursuing growth through new therapies.

Keytruda’s role in Merck’s oncology franchise

Keytruda, Merck’s PD-1 inhibitor used in a wide range of cancer indications, has grown into one of the largest pharmaceutical products globally. As noted, Q1 2024 revenue of about $6.9 billion represented year-on-year growth of roughly 19% versus the prior-year quarter, based on Merck’s Keytruda data. For Merck stock, that growth rate is critical because Keytruda now makes up a significant proportion of group sales, meaning trends in oncology can have outsized impact on consolidated earnings.

The product’s strong trajectory reflects its broad label across lung cancer, melanoma, head and neck cancers and other solid tumors. Merck has continued to pursue additional indications and earlier-line settings for Keytruda, including in combination therapies, which it expects will support revenue in the medium term. The detailed breakdown of results in Q1 2024 showed that oncology, led by Keytruda, was the largest therapeutic area contributor to Merck’s revenue mix, as summarized by the segment performance tables. This concentration reinforces why investors closely track regulatory news and clinical trial updates related to Keytruda when gauging the outlook for Merck stock.

At the same time, Merck must manage the long-term risk associated with Keytruda’s patent protection. While the drug still has years of exclusivity, the market is already considering scenarios for competition from new immune-oncology agents and biosimilars once patents expire. Merck’s continued investment in next-generation oncology programs and other therapeutic areas is partly a response to that challenge. For Merck stock, successful diversification of the revenue base beyond Keytruda can help mitigate valuation swings that might otherwise arise in response to single-product headlines.

Vaccines, animal health and diversification benefits

Merck & Co. is not solely reliant on oncology. Its vaccines business, which includes products such as Gardasil, also contributes materially to earnings. In Q1 2024, Gardasil achieved roughly $2.5 billion in sales, up from about $2.1 billion in the same quarter in 2023, corresponding to growth of nearly 19%, as outlined in Merck’s segment disclosures. That performance adds another pillar of double-digit top-line expansion alongside Keytruda, widening the base of products underpinning Merck stock’s earnings profile.

Beyond human health, Merck’s animal health division generates recurring revenue through vaccines and pharmaceuticals for livestock and companion animals. In Q1 2024, animal health sales came in around $1.5 billion, modestly higher than the prior-year quarter’s approximately $1.4 billion, reflecting mid-single-digit growth, according to figures in Merck’s earnings tables. For investors, animal health can act as a stabilizing segment, offering less patent volatility than certain human medicines and providing diversified cash flows that support the overall Merck group.

Merck’s broader portfolio also includes hospital acute care products and cardiovascular medicines, which round out the business mix. While these areas may not deliver the same headline growth rates as oncology and vaccines, their contribution to steady revenue and earnings can be important when markets reassess risk and shift capital into defensive sectors. The balanced revenue split visible in Merck’s Q1 2024 report gives a more nuanced picture of the company than a pure focus on Keytruda alone, and that nuance often matters for how Merck stock is valued compared with more narrowly specialized peers.

Guidance and medium-term outlook signals

In its first quarter 2024 communication, Merck & Co. reaffirmed and updated full-year guidance ranges, offering investors a reference point for expected revenue and earnings. The company guided for 2024 revenue of approximately $62.7 billion to $64.2 billion, representing growth versus 2023’s reported sales of about $60.1 billion, as presented in the guidance section. That range implies mid-single to high-single-digit growth at the group level, anchored in ongoing strength from Keytruda and Gardasil.

Merck also projected 2024 GAAP EPS from continuing operations in a range of roughly $1.42 to $1.50, with non-GAAP EPS targeted between about $8.44 and $8.54, according to its Q1 2024 guidance update. These figures frame market expectations for Merck stock over the coming quarters and provide a benchmark against which future results will be assessed. The ability to deliver within or above these ranges will likely influence how the shares trade around earnings dates.

For investors, guidance also interacts with valuation. At recent market prices, Merck stock has traded at a forward price-to-earnings multiple that reflects both its defensive characteristics and its growth in oncology and vaccines. The 2024 non-GAAP EPS guidance, combined with the company’s dividend payout and R&D profile, helps market participants assess whether the current valuation remains reasonable in light of macroeconomic conditions and sector comparables. While those comparative metrics shift over time as estimates change, the guidance interval provides an anchor in a volatile information environment.

Keytruda and oncology revenue focus

Keytruda’s contribution to Merck’s overall revenue profile means that oncology trends are among the most watched indicators in the company’s quarterly reports. With Q1 2024 Keytruda sales of approximately $6.9 billion, up from around $5.8 billion in Q1 2023, Merck’s oncology revenues showed both scale and growth, as detailed in the product-level tables. This nearly $1.1 billion year-on-year increase underscores the centrality of oncology in Merck’s earnings story and explains why Merck stock often reacts to incremental updates from cancer trials and regulatory decisions.

However, reliance on a single mega-blockbuster also creates strategic pressure to expand the pipeline. Merck’s clinical development portfolio includes multiple late-stage assets targeting various cancers and cardiometabolic conditions, and the company continues to invest heavily in immuno-oncology combinations involving Keytruda. The success of those programs will influence how quickly Merck can pivot to a more diversified oncology franchise in the years leading up to and beyond Keytruda’s patent expirations. For market participants, the balance between current Keytruda cash flows and future pipeline potential is a recurring theme when discussing Merck stock.

International expansion is another dimension of Keytruda’s trajectory. Merck’s results show strong uptake of the drug in major markets outside the United States, including Europe and parts of Asia, according to regional breakdowns referenced in Merck’s disclosures. That geographic spread can provide a partial buffer against localized reimbursement changes or competitive moves, though global regulatory and pricing environments remain key considerations for long-term holders of Merck stock.

Representative product: Keytruda’s revenue engine

Among Merck’s broad product suite, Keytruda stands out as a representative product line because of its scale, growth rate and strategic importance. As noted, Keytruda generated about $6.9 billion in revenue in Q1 2024 alone, compared with approximately $5.8 billion in Q1 2023, according to Merck’s product performance tables. That makes Keytruda one of the world’s top-selling medicines and a core source of cash flow that funds R&D, dividends and potential acquisitions.

Keytruda’s indication set covers multiple tumor types, and Merck has pursued a strategy of continuously broadening its label. The mechanisms of action, centered on PD-1 pathway inhibition, have proven versatile across cancers, and ongoing trials aim to push the drug into earlier stages of disease and new combinations. This dynamic is why Keytruda often features prominently in Merck’s investor presentations and why many analysts view its trajectory as a primary factor in Merck stock’s valuation. While no single product can define an entire company forever, Keytruda’s current role is unusually large even by blockbuster standards.

Merck stock and recent market levels

Merck & Co. stock is traded on the New York Stock Exchange under the symbol MRK, and it is a constituent of the S&P 500 index, giving it a prominent role in healthcare and broad-market portfolios. As of 30 April 2024, shortly after the Q1 2024 earnings release cited above, Merck’s market capitalization stood around $320 billion based on a share price near $130 and the reported diluted share count, according to calculations using data from Merck’s filings. That valuation places Merck among the largest global pharmaceutical companies and underscores how widely held the stock is across institutional and retail investors.

On recent trading days around the end of April 2024, Merck stock changed hands close to the $130 level on NYSE, a price zone that was near the upper end of its 52-week range, based on quote data summarized by major market portals referencing that period. This proximity to a 52-week high reflects both strong recent results and broader investor interest in defensive growth names during periods of macro uncertainty. For holders of Merck stock, attention often turns to whether earnings momentum, dividend yield and pipeline updates can justify sustaining or extending prices at these elevated levels over the medium term.